Canada markets closed

NeuroMetrix, Inc. (NURO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
14.90-1.14 (-7.11%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close16.04
Open15.90
Bid14.63 x 1000
Ask14.77 x 3000
Day's Range13.88 - 15.95
52 Week Range1.39 - 38.75
Volume1,756,335
Avg. Volume7,820,455
Market Cap83.871M
Beta (5Y Monthly)2.81
PE Ratio (TTM)N/A
EPS (TTM)-0.30
Earnings DateOct. 20, 2021 - Oct. 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar. 28, 2007
1y Target EstN/A
  • NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia
    GlobeNewswire

    NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia

    WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research. The article is available online at the journal website. The article reports an intention-to-treat analysis of a double-blind, randomized, sham-controlled trial that compared 3-months of at-home treatment with a standard (active) or low

  • NeuroMetrix Reports Q2 2021 Financial Results
    GlobeNewswire

    NeuroMetrix Reports Q2 2021 Financial Results

    WOBURN, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. Highlights: Revenue of $2.2 million improved 63% from $1.4 million in Q2 2020. The Q2 2020 results were adversely affected by a pandemic-related decline in customer orders. Gross margin on revenue

  • Companies Like NeuroMetrix (NASDAQ:NURO) Can Afford To Invest In Growth
    Simply Wall St.

    Companies Like NeuroMetrix (NASDAQ:NURO) Can Afford To Invest In Growth

    Just because a business does not make any money, does not mean that the stock will go down. Indeed, NeuroMetrix...